



The Retina Society

49TH ANNUAL SCIENTIFIC MEETING

The U.S. Grant Hotel SAN DIEGO, CALIFORNIA

SEPTEMBER 14 - 17, 2016

2016

2016



2016

PARTICIPANT'S REGISTRATION PACKET

DEAR RETINA SOCIETY MEMBERS, SPOUSES & GUESTS

INCLUDED IN THIS PACKET PLEASE FIND:

- 1) Meeting registration information
- 2) Hotel reservation information
- 3) Program-in-brief
- 4) Social program (please bring home to spouse or guest)
- 5) Preliminary programs



The 49th Annual Scientific Session of The Retina Society, to be held at the **U.S. GRANT HOTEL IN SAN DIEGO, CA, SEPTEMBER 14 - 17, 2016**, promises to be one of our best ever. With by far a record number of abstract submissions, we have been able to assemble a superlative program of podium, poster, and award presentations. We expect that the excellent science combined with lively debate, social exchange, culinary delights, and cultural adventures will make for a truly memorable experience for members and guests alike.

NONMEMBER GUESTS: Members may invite one nonmember practicing physician guest to attend the meeting provided the member is also attending. Please contact Judy Cerone Keenan (retinasoc@aol.com; 617.227.8767) if you would like a guest to receive this registration material. Fellows-in-training are welcome to register without a sponsor.

ONLINE REGISTRATION: To register for the meeting, please log in to the member area at www.retinasociety.org. Nonmember guests will be asked to create a profile, then proceed to registration.

Below is a brief description of our social events. Please see more detailed information within the packet and indicate which events you will attend when registering online. Please be sure to sign up ahead of time as space is limited and adding on at the meeting may not be possible.

WELCOMING RECEPTION | WEDNESDAY EVENING. Following the annual Interesting Cases and Video Conference and first scientific session, join us to greet old friends and make new ones in the beautiful Horton Plaza Park directly in front of the hotel. This historic and newly-renovated urban oasis will serve as a fabulous outdoor setting for our opening festivity.

BALBOA PARK | THURSDAY EVENING. Join us for a reception and dinner at the famous Museum of Man in Balboa Park, just blocks from the U.S. Grant Hotel. Reserved exclusively for the Retina Society, this fabulous anthropological museum is housed in a beautiful and iconic building with Spanish mission style architecture. Before and after our special dinner in this unique venue, deepen your understanding of the human experience by exploring the museum's fascinating exhibits. Then admire the beautiful gardens and architecture of surrounding Balboa Park, San Diego's cultural, historical, and artistic hub.

BANQUET | FRIDAY EVENING. Our traditional black-tie optional event will be unforgettable with a delectable dinner and dancing in the ornate Presidential Ballroom of the historic U.S. Grant Hotel.

BE SURE TO CHECK DETAILED INFORMATION on these events inside. Please also check our web site from time to time for updated meeting information. Have a wonderful summer and see you in beautiful San Diego in September.

The Program Committee

MEETING FEES / U.S. GRANT REGISTRATION INFO

PLEASE REGISTER ONLINE AT WWW.RETINASOCIETY.ORG

You may pay by credit card (Visa/MC/AMEX).

FEES	UNTIL AUGUST 15	AUGUST 16 – SEPTEMBER 1	SEPTEMBER 2 – ONSITE
MEMBER	\$650	\$750	\$1,000
NONMEMBER PHYSICIAN GUEST	\$650	\$750	\$1,000
FELLOW-IN-TRAINING*	\$350	\$450	\$ 550

**Including Fellows, Residents, Medical Students*

SPOUSE/ACCOMPANYING GUEST	\$450	\$650	\$ 700
CHILDREN ATTENDING SOCIAL ACTIVITIES		UNDER AGE 6 \$0	AGES 6 – 18 YEARS \$ 300

FEES ABOVE INCLUDE: Continental Breakfast/Breaks/Lunch (Physicians), Welcome Reception, Thursday Evening Museum of Man and Banquet

SPOUSE/GUEST TOUR — See Description on Page 5

Thursday, visit to La Jolla Galleries, Shopping & Lunch

\$100 PER PERSON

MEETING CANCELLATION AND REFUND POLICY: CANCELLATIONS OR REQUESTS FOR REFUNDS MUST BE MADE IN WRITING. THOSE RECEIVED ON OR BEFORE **AUGUST 15** WILL BE REFUNDABLE LESS A \$100 SURCHARGE; CANCELLATIONS RECEIVED AFTER AUGUST 15 ARE NONREFUNDABLE.

NOTE: UNLESS YOU INDICATE ON THE REGISTRATION THAT YOU DO NOT WANT YOUR CONTACT INFORMATION SHARED, IT WILL BE USED IN AN ATTENDEE BOOKLET AS WELL AS OUR LEAD RETRIEVAL SYSTEM.

HOTEL RESERVATIONS

Click below to go the U.S. Grant registration page

(for The Retina Society):

<https://www.starwoodmeeting.com/Book/retina>



PRELIMINARY PROGRAM-IN-BRIEF

WEDNESDAY, SEPTEMBER 14, 2016

9:00 am – 12:00 noon	The Retina Society Executive Committee Meeting — VINTAGE
11:00 am	Speaker Ready Room Opens — SICKLES ROOM
12:00 noon	Exhibit Set-up — CELESTIAL BALLROOM
12:00 – 5:00 pm	Meeting Registration — PRESIDENTIAL FOYER
1:00 – 4:15 pm	Interesting Retinal Cases/Video Presentations — PRESIDENTIAL BALLROOM
5:00 – 6:38 pm	Scientific Session — PRESIDENTIAL BALLROOM
7:00 – 10:00 pm	Welcoming Reception — HORTON PLAZA

THURSDAY, SEPTEMBER 15, 2016

7:00 am	Meeting Registration — PRESIDENTIAL FOYER Exhibits/Continental Breakfast/Breaks — CELESTIAL BALLROOM
7:30 am – 12:30 pm	Scientific Session — PRESIDENTIAL BALLROOM
12:30 – 1:00 pm	Scientific Meeting Attendees Lunch — PALM COURT
1:00 – 2:00 pm	Dessert and Poster Viewing — CRYSTAL/GRANT
2:03 – 5:15 pm	Scientific Session — PRESIDENTIAL BALLROOM
6:30 – 10:00 pm	Reception and Dinner — MUSEUM OF MAN

FRIDAY, SEPTEMBER 16, 2016

7:00 am	Registration — PRESIDENTIAL FOYER Continental Breakfast/Exhibits/Breaks — CELESTIAL BALLROOM
7:30 am – 12:50 pm	Scientific Session — PRESIDENTIAL BALLROOM
12:50 – 1:45 pm	Scientific Meeting Attendees Lunch — PALM COURT
1:45 – 5:30 pm	Scientific Session — PRESIDENTIAL BALLROOM
6:00 – 7:00 pm	Reception — TBA
7:00 – 11:00 pm	BANQUET — PRESIDENTIAL BALLROOM

SATURDAY, SEPTEMBER 17, 2016

7:00 am	Registration — PRESIDENTIAL FOYER Continental Breakfast/Exhibits/Breaks — CELESTIAL BALLROOM
7:30 – 11:56 am	Scientific Session — PRESIDENTIAL BALLROOM ADJOURN

SOCIAL PROGRAM



WEDNESDAY, SEPTEMBER 14

7:00 – 10:00 PM

WELCOME RECEPTION

HORTON PLAZA

Join us at the newly opened Horton Plaza steps from the Grant Hotel to meet and greet new and old friends! The plaza sports a recent \$12 million renovation including the restoration of the iconic fountain, a new semi-circular amphitheater and historically appropriate details including decorative elements inspired by the tradition of woven basket patterns from the Kumeyaay Native-American people.



THURSDAY & FRIDAY


SEPTEMBER 15 AND 16

7:30 – 10:00 AM

HOSPITALITY SUITE

SYCUAN PARLOR, SECOND LEVEL

Spouse and guest hospitality suite will be available for coffee, tea, and breakfast, as well as a place to meet friends. On Saturday, spouses and guests are welcome to continental breakfast in the *Celestial Ballroom*.



THURSDAY, SEPTEMBER 15

9:30 AM – 3:00 PM

EXPLORE LA JOLLA'S ART

GUEST/SPOUSE TOURS

La Jolla is known as San Diego's jewel by the sea. In the village, photography, sculpture and paintings seem to spill out into the streets, offering a pleasant way to spend an afternoon. Discover the best of La Jolla's art galleries, enjoy olive oil or chocolate tasting, then savour lunch at the renowned Georges at the Cove.



continues on next page

SOCIAL PROGRAM

continued from previous page

BALBOA PARK, named for the Spanish maritime explorer Vasco Núñez de Balboa, is a 1,200-acre urban cultural park filled with open space areas, natural vegetation zones, green belts, gardens, and walking paths, several world-class museums and theaters, and the world-famous San Diego Zoo. Placed in reserve in 1835, the park's site is one of the oldest in the United States dedicated to public recreation.



California Tower/Museum of Man

THURSDAY, SEPTEMBER 15

6:30 - 10:00 PM

RECEPTION & DINNER

MUSEUM OF MAN, BALBOA PARK

Located beneath the magnificently decorated 200-foot California Tower, the San Diego Museum of Man is a museum dedicated to the study of anthropology. The landmark building was originally constructed for the Panama-California Exposition in 1915 - 1916. Savvy Strings, an all female group, will perform classical and contemporary songs throughout the evening.




Presidential Ballroom

SATURDAY, SEPTEMBER 16

7:00 - 11:00 PM

BANQUET - BLACK TIE OPTIONAL U.S. GRANT HOTEL, PRESIDENTIAL BALLROOM

The Presidential Ballroom, lavishly appointed, pays tribute to the fourteen U.S. Presidents who have stayed at the hotel. Join us for dinner, dancing and conviviality.



SPECIAL THANKS TO OUR EXHIBITORS

Alcon
Alimera Sciences
Allergan
Bausch & Lomb
Carl Zeiss Meditec
Genentech
Heidelberg Engineering
LKC Technologies
Wolters Kluwer Health
Mallinckrodt Pharmaceuticals
Notal Vision
Oculus Surgical, Inc
OD-OS GmbH
Optos
Optovue
Pine Pharmaceuticals
Regeneron
Retina Today
Retinal Physician
Retinal Specialist
Second Sight Medical Products
Sparks Therapeutics
ThromboGenics
Topcon Medical Systems

(AT TIME OF PRINTING)

CME STATEMENT

DISCLOSURE:

All speakers have been asked to disclose any relative financial relationships they may have with commercial interests. The presence or absence of relationships as well as off-label discussion of products will be disclosed at the time of the meeting.

TARGET AUDIENCE:

Vitreoretinal ophthalmologists who are members and guests of members of the Retina Society, as well as fellows-in-training

DESCRIPTION:

This annual meeting is intended to increase the physician's knowledge, skills and performance to provide services for patients. Topics for discussion will include but are not limited to age-related macular degeneration, diabetic retinopathy, tumors, infections, surgery for retinal detachment and macular disease, pediatrics, imaging. At the Interesting Retinal Cases Session and Video Conference, physicians will be able to participate in discussion and reach a conclusion on treatment of various interesting vitreoretinal cases presented by participants. The attendee's basic knowledge and treatment skills will be enhanced by the information presented and subsequent discussions.

OBJECTIVES:

This conference is designed to address the needs and interests of vitreoretinal surgeons. Upon completion of this conference, attendees can expect to achieve the following overall objectives:

1. Apply evidence-based data from randomized, clinical trials to help form treatment plans for patients with medical retinal diseases such as age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. Utilize data from smaller trials and case series to help individualize such treatments for patients with different responses to therapy, such as persistent fluid, elevated intraocular pressure, or inflammation
2. Apply advanced imaging technologies such as OCT-angiography and Ultra-widefield angiography to recognize pathology not previously detected or understood. This includes far peripheral pathology, subtle choroidal neovascularization, and appreciation of retinal vascular abnormalities not noted with conventional imaging modalities.
3. Incorporate new surgical tools, techniques, and intraoperative imaging modalities to improve patient outcomes and minimize complications.

INTERESTING RETINAL CASE/VIDEO CONFERENCE

WEDNESDAY, SEPTEMBER 14, 2016

INTERESTING CASES I

MODERATORS: Michael Jumper, MD and Fernando Arevalo, MD, FACS

- 1:00 pm Doctor My Eyes
Jose Pulido, MD
- 1:05 Severe Vision Loss in a Surgeon (Tree Surgeon, That Is)
Michael Jumper, MD
- 1:10 Laser Tag
Shlomit Schaal, MD, PhD
- 1:15 Purtscher-like Retinopathy Secondary to Gemcitabine Therapy
Jaclyn Kovach, MD
- 1:20 Macular Enigma
Mark Johnson, MD
- 1:25 Release of Vitreomacular Traction in Diabetic Macular Edema with Aflibercept
Robert Wiznia, MD
- 1:30 Intravitreal Triamcinolone in Susac's Syndrome
Fernando Arevalo, MD, FACS
- 1:35 Subretinal Suture Misdirection During Trabeculotomy
Robert Sisk, MD
- 1:40 Intraocular Lens Surprise after Pars Plana Vitrectomy
Rahul Khurana, MD
- 1:45 Mystery Case
Jerry Shields, MD
- 1:50 Infection, Inflammation, Both, Or Neither? The Not-So-Binary Case of Patient O-1-O
Scott McClintic, MD
- 1:55 Retinal Vasculopathy in Cutis Marmorata Telangiectatica Congenita
Cagri Besirli, MD, PhD
- 2:00 Vision Loss in a Patient with Primary Pulmonary Hypertension and Long-term Use of Sildenafil
Christina Weng, MD, MBA
- 2:05 Bilateral Pigmentation of the Posterior Segment
John Mason III, MD
- 2:10 Total Exudative Retinal Detachment
Arun Singh, MD

INTERESTING CASES II

MODERATORS: Carol Shields, MD and Prithvi Mruthyunjaya, MD

- 2:20 pm Bilateral Vision Loss Associated with Progressive Outer Retinal Abnormality
Gregg Kokame, MD, MMM
- 2:25 Serous Retinal Detachment in Treated Retinoblastoma
Anita Agarwal, MD
- 2:30 Cancer Associated Retinopathy
Charles Barr, MD
- 2:35 An Unusual Presentation of Spontaneous Epiretinal Membrane Resolution
James Lin, MD

WEDNESDAY, SEPTEMBER 14, 2016

- 2:40 pm Unknown Reflective Foreign Body Following Vitrectomy for Retinal Detachment Repair
Jonathan Chang, MD
- 2:45 Coats' Disease-Associated Vasoproliferative Tumor of the Retina with Epiretinal Membrane, Uveitis, and Uncontrolled Glaucoma
John Allen, MD
- 2:50 Retinal Lesion after Returning from Haiti
Robert Mittra, MD
- 2:55 Late Onset Retinal Degeneration and Progressive Visual Loss
Thiran Jayasundera, MD
- 3:00 A Curious Case of Perivascular Infiltrates
Sandeep Randhawa, MD
- 3:05 A Soupy Mess in a Patient with Scleritis Treated with Systemic TNF-Alpha Inhibition
Prithvi Mruthyunjaya, MD
- 3:10 Bilateral Central Retinal Vein Occlusion due to Polyclonal Gammopathy
Kirk Packo, MD
- 3:15 Mystery Case
Carol Shields, MD
- 3:20 A Tale of Two Brothers: An Interesting Phenotype-Genotype Correlation
Seema Garg, MD, PhD
- 3:25 Orange Tumor?
Tara McCannel, MD, PhD
- 3:30 White Dots Gone Wild
Monica Michelotti, MD

VIDEO PRESENTATIONS

MODERATORS: Kirk Packo, MD and Raymond Iezzi, MD, MS

- 3:40 Its a Terson's Again....
Audina Berrocal, MD
- 3:45 Toward More Precise Subretinal Therapeutic Delivery: New Techniques and Instrumentation
Allen Ho, MD, FACS
- 3:50 Diabetic Tractional Detachment. Mixed Gauges, miOCT, and Preop Planning
Tamer Mahmoud, MD, PhD
- 3:55 "Stretch" Technique for Management of Retinal Detachment Associated with Severe PVR
Homayoun Tabandeh, MD, MS
- 4:00 Microscope Scleral Buckling with Chandelier and Illuminated Laser Probe
Maria Berrocal, MD
- 4:05 Broad ILM Peeling for No Face Down Macular Hole Repair
Raymond Iezzi, MD, MS
- 4:10 Adjunctive Use of Platelet-Rich Plasma in Repair of a Myopic Macular Hole/Schisis-Associated Retinal Detachment: Intraoperative OCT Findings
Scott Walter, MD, MSc
- 4:15 Analysis of an Epiretinal Membrane that Developed after Subretinal Delivery of a Cell Therapy Product in a Subject with Retinitis Pigmentosa
Rand Spencer, MD

PRELIMINARY SCIENTIFIC SESSIONS

WEDNESDAY, SEPTEMBER 14, 2016

5:00 pm	Welcome Mark Johnson, MD, <i>President</i>
	OTHER MACULAR DISEASE PRESIDING OFFICER: Mark Johnson, MD MODERATOR: Jason Hsu, MD
5:05	The LIBERTY Study: Assessing the Impact of Self-monitoring on Visual Outcomes in Previously Treated Patients with Neovascular Age-related Macular Degeneration Pravin Dugel, MD
5:11	Discussion
5:14	Inner-retinal Irregularity Index as a New Marker for Visual Prognosis in Idiopathic Epiretinal Membrane Kyu Hyung Park, MD
5:20	Discussion
5:23	Spontaneous Avulsions of the Internal Limiting Membrane—A Possible Cause of Epiretinal Membrane Formation Kirk Packo, MD
5:29	Discussion
5:32	Increased Vitreopapillary Traction in Eyes with Small Optic Nerves May Contribute to the Development of Non-arteritic Ischemic Optic Neuropathy Tongalp Tezel, MD
5:38	Discussion
5:41	Early Spectral Domain Optical Coherence Tomography Findings after Acute Spontaneous Vitreomacular Traction Release Jason Hsu, MD
5:47	Discussion
5:50	*Efficacy and Safety Outcomes for Ocriplasmin Intravitreal Injection from Multiple Prospective Clinical Trials (MIVI-TRUST, OASIS, and ORBIT) Kapil Kapoor, MD
5:56	*Macula Society Collaborative Retrospective Study of Ocriplasmin for Vitreomacular Traction Jennifer Lim, MD
6:02	*Combined Discussion
6:05	*Pharmacologic Closure Rate of Full Thickness Macular Hole with Ocriplasmin Priya Sharma
6:11	*Macular Hole Enlargement after Ocriplasmin Injection for Full-thickness Macular Hole Daniel Roth, MD
6:17	*Combined Discussion
6:20	Lamellar Macular Hole: Two Distinct Clinical Entities? Jean-Pierre Hubschman, MD
6:26	Discussion

WEDNESDAY, SEPTEMBER 14, 2016

6:29 pm	Yellow Micropulse Laser vs. Photodynamic Therapy in Eyes with Chronic Central Serous Chorioretinopathy. Results of the Pan American Collaborative Retina Study (PACORES) Group Lihteh Wu, MD
6:35	Discussion
6:38	ADJOURN

THURSDAY, SEPTEMBER 15, 2016

DIABETIC RETINOPATHY

PRESIDING OFFICER: Jeffrey Heier, MD

MODERATOR: Victor Gonzalez, MD

7:30 am	<i>Analysis of Intravitreal Levels of Neurotrophins in Diabetic Retinopathy</i> Joseph Boss, MD
7:35	*Association between Baseline Characteristics and Changes in Diabetic Retinopathy Severity Scale (DRSS) Score: Analyses from the VISTA and VIVID Studies Rishi Singh, MD
7:41	*Visual and Anatomic Outcomes Before and After Cataract Surgery in Patients Treated for Diabetic Macular Edema (DME) in the VISTA and VIVID Studies Andrew Moshfeghi, MD
7:47	*Change in Retinal Perfusion Status in Patients Treated for Diabetic Macular Edema (DME) in the VISTA Study Charles Wykoff, MD
7:53	*Combined Discussion
7:57	Randomized Trial Comparing Ranibizumab Monthly to Treat & Extend With and Without Angiography-guided Laser for Diabetic Macular Edema (DME): TREX-DME 1 Year Outcomes John Payne, MD
8:03	Discussion
8:06	Predicting Visual Acuity Response to Anti-VEGF DME Therapy in Protocol I: A Post-hoc Analysis of Outcomes in Patient with Limited (<5 letter) and Intermediate (5-9 letter) Response at 12 Weeks Victor Gonzalez, MD
8:12	Discussion
8:15	Quantifying Microvascular Density and Morphology in Diabetic Retinopathy Using Spectral Domain Optical Coherence Tomography Angiography (SD-OCTA) Amir Kashani, MD
8:21	Discussion
8:24	Distribution of Hemorrhages and/or Microaneurysms (H/Ma) Identified on Ultra-wide Field (UWF) Retinal Images and the Risk of Progression Over Four Years Paolo Antonio Silva, MD
8:30	Discussion
8:33	*Safety and Efficacy of Intravitreal Ranibizumab for Diabetic Macular Edema in Eyes Previously Treated with Intravitreal Bevacizumab: A Randomized Dual-Arm Comparative Dosing Trial. The REACT Study Justis Ehlers, MD

- 8:39 am *Ranibizumab (0.3mg) for Persistent Diabetic Macular Edema After Recent, Frequent and Chronic Bevacizumab: 1 Year Trial Results
Dennis Marcus, MD
- 8:45 *Conversion of Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema
Ali Khan, MD
- 8:51 *Combined Discussion
- 8:55 Short-term Results of Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema in Highly Treated Eyes
Sumit Shah, MD
- 9:01 Discussion
- 9:04 *Ranibizumab Induces Regression of Diabetic Retinopathy (DR) in Over Seventy-five Percent of Patients with Highest Risk Non-proliferative Diabetic Retinopathy (NPDR), Independent of Examined Baseline Characteristics
Geeta Lalwani, MD
- 9:10 *The Clinical Importance of Changes in Diabetic Retinopathy Severity Score
Michael Ip, MD
- 9:16 *Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion
Dante Pieramici, MD
- 9:22 *Combined Discussion
- 9:26 Potential Beneficial Effect of Low Dose Danazol in Combination with Renin Angiotensin Inhibitors in Diabetic Macular Edema: Results of the Optimeyes Trial
Michael Singer, MD
- 9:32 Discussion
- 9:35 North Carolina Diabetic Retinopathy Telemedicine Network
Seema Garg, MD
- 9:41 Discussion
- 9:44 REFRESHMENT BREAK/EXHIBITS
- SURGERY I**
- PRESIDING OFFICER: **Harry Flynn Jr, MD**
- MODERATOR: **Judy Kim, MD**
- 10:14 am *Outcomes After Failed Pneumatic Retinopexy for Retinal Detachment*
Joseph Anaya, MD
- 10:19 *Macular Hole After Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment*
Harry Flynn Jr, MD
- 10:24 *Anatomic and Visual Outcomes for Complex Rhegmatogenous Retinal Detachment (RDD) in the Era of Small Gauge Vitreoretinal Surgery*
Homayoun Tabandeh, MD
- 10:29 *Effect of Scleral Buckling on Eyes that had Previously Undergone LASIK Surgery*
Thomas Friberg, MD
- 10:34 *Persistent ICG Fluorescence Following Macular Hole Repair*
Judy Kim, MD

10:39 am	Peeling or Not Peeling the Internal Limiting Membrane in Macular Pucker Surgery: A Microperimetric Response Guido Ripandelli, MD
10:45	Discussion
10:48	*Should Epiretinal Membranes be Peeled Before Vision Drops Below 20/40? John Pollack, MD
10:54	*Macular Pucker Surgery Outcomes in Good Vision Eyes Colin McCannel, MD
11:00	*Combined Discussion
11:03	Internal Limiting Membrane Peeling (ILMP) Reabsorbs Macular Edema (ME) and Improves Visual Acuity Precisely because it is a Retinal Trauma of Mechanical Nature Claude Boscher, MD
11:09	Discussion
11:12	Management of Focal Vitreomacular Traction with Pneumatic Vitreolysis Clement Chan, MD
11:18	Discussion
11:21	Optical Coherence Tomography-guided Short-duration Face-down Positioning after Vitrectomy for Macular Hole Theodore Leng, MD
11:27	Discussion
11:30	Autologous Neurosensory Retinal and Choroidal Free Flap for Closure of Refractory Large Macular Holes Dilraj Grewal, MD
11:36	Discussion
11:39	Displacement of Submacular Hemorrhage with Subretinal Air. Initial U.S. Experience Tamer Mahmoud, MD
11:45	Discussion
11:48	FELLOWSHIP RESEARCH AWARD PRESENTATION INTRODUCTION: David Zacks, MD Protective Effect of Mesenchymal Stem Cell Derived Exosomes in a Model of Retinal Ischemia Elad Moisselev, MD
12:03 pm	RETINA RESEARCH AWARD OF MERIT — Charles L. Schepens Lecture INTRODUCTION: Kirk Packo, MD Evolution of Vitreoretinal Techniques and Technologies Steve Charles, MD
12:33 – 1:03	LUNCH
1:03 – 2:03	POSTER VIEWING AND DESSERT RETINAL VASCULAR DISEASE PRESIDING OFFICER: Julia Haller, MD MODERATOR: Adrienne Scott, MD
2:03	<i>Ultra-wide Field Retinal Imaging in the Staging and Management of Sickle Cell Retinopathy</i> Adrienne Scott, MD

- 2:08 pm *Late-phase Fluorescein Angiographic Findings which Predict Capillary Dropout and Subsequent Drug Treatment which can Lead to Capillary Preservation*
Michael Trese, MD
- 2:13 Norrin Regulates Vascular Development and Capillary Regeneration
Kimberly Drenser, MD
- 2:19 Discussion
- 2:22 *Late-stage Management of Macular Edema Secondary to Retinal Vein Occlusion: Collective Analysis of the BRAVO, CRUISE, HORIZON, and SHORE Studies
Robert Bhisitkul, MD
- 2:28 *Long-term Outcomes of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Treated with Intravitreal Bevacizumab. Results of the Pan American Collaborative Retina Study (PACORES) Group
Dhariana Acon, MD
- 2:34 *Combined Discussion
- 2:37 Combination Therapy of Ranibizumab Plus Laser-induced Chorioretinal Anastomosis for Central Retinal Vein Occlusion
Ian McAllister, MD
- 2:43 Discussion
- 2:46 Oral Niacin as a Modulator for Central Retinal Vein Occlusion
Yannis Paulus, MD
- 2:52 Discussion
- 2:55 **REFRESHMENT BREAK/EXHIBITS**
- TUMORS**
- PRESIDING OFFICER: Timothy Murray, MD**
- MODERATOR: Amy Scheffler, MD**
- 3:25 pm *Genetic Risk Factors for Radiation Vasculopathy*
Thanos Papakostas, MD
- 3:30 *Novel Classification System for Combined Hamartoma of the Retina and Retinal Pigment Epithelium*
Vaidehi Dedania, MD
- 3:35 *Germline BAP1 Mutation in Familial Uveal Melanoma: Report of Twenty-six New Families*
Colleen Cebulla, MD
- 3:40 *Intra-arterial Chemotherapy in Very Small Infants (< 10kg) with Retinoblastoma*
Amy Scheffler, MD
- 3:45 Association between Choroidal Nevus Risk Factors and Gene Expression Profile Prognostic Class
William Harbour, MD
- 3:51 Discussion
- 3:54 Mushroom Shaped Choroidal Lesions other than Melanoma
Jerry Shields, MD
- 4:00 Discussion
- 4:03 Tumor Regression Patterns Based on Gene Expression Profile Testing Radiotherapy for Uveal Melanoma: A Multicenter Study
Prithvi Mruthyunjaya, MD
- 4:09 Discussion

4:12 pm	Optical Coherence Tomography Angiography of the Macula after Plaque Radiotherapy of Choroidal Melanoma: Comparison of Irradiated versus Non-irradiated Eyes in Sixty-five Patients Carol Shields, MD
4:18	Discussion
4:21	Prognostic Value of Vascular Congestion in Mushroom-shaped Uveal Melanomas Treated with Proton Beam Irradiation Leonidas Zografos, MD
4:27	Discussion
4:30	Survival in a Large Cohort of Patients with Metastasis from Uveal Melanoma Evangelos Gragoudas, MD
4:36	Discussion
4:39	Vision Loss Following Episcleral Brachytherapy: A Risk Calculator Arun Singh, MD
4:45	Discussion
4:48	Vitreoretinal Surgical Management of Uveal Melanoma: Unique Intraoperative Findings and Outcomes Timothy Murray, MD
4:54	Discussion
4:57	Visual Benefit of Iodine-125 Brachytherapy with Vitrectomy and Silicone Oil for Large Choroidal Melanoma: 1-to-1 Matched Case-control Series Tara McCannel, MD
5:03	Discussion
5:06	Safety and Efficacy of 25g Vitrectomy with Needle Biopsy of Choroidal Melanoma for Gene Expression Profiling (GEP) during Brachytherapy John Mason III, MD
5:12	Discussion
5:15	ADJOURN

FRIDAY, SEPTEMBER 16, 2016

AGE-RELATED MACULAR DEGENERATION I

PRESIDING OFFICER: **Allen Ho, MD**

MODERATOR: **Deeba Husain, MD**

7:30 am	<i>Prevalence of Drusen and Conversion to Neovascular Age-related Macular Degeneration in Fellow Eyes in the HARBOR Study</i> Caroline Bauman, MD
7:35	<i>Type 1 versus Type 3 Neovascularization in Pigment Epithelial Detachments (PEDs) Associated with Age-related Macular Degeneration after Anti-VEGF Therapy in the EVEN Study: Post-hoc Analysis of a Prospective Study</i> Xuejing Chen, MD
7:40	<i>Correlation of Optical Coherence Tomographic Hyper-reflective Foci with Visual Outcomes after Treatment in Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy</i> Hyung Chan Kim, MD

7:45 am	En-face Spectral Domain Optical Coherence Tomography in Polypoidal Choroidal Vasculopathy Gregg Kokame, MD
7:51	Discussion
7:54	Changes in Dark Adaptation and Structure by OCT in Age-related Macular Degeneration Deeba Husain, MD
8:00	Discussion
8:03	Adjunctive Indocyanine Green Angiography-directed Verteporfin Photodynamic Therapy for the Treatment of Persistent Disease Activity in Neovascular Age-related Macular Degeneration Priyatham Mettu, MD
8:09	Discussion
8:12	Impact of Anti-VEGF Therapy on Photoreceptors in Patients with Exudative Age-related Macular Degeneration Shintaro Nakao, MD
8:18	Discussion
8:21	Evaluation of Choroidal Perfusion with Rapid-scan Plane Wave Ultrasonography Jackson Coleman, MD
8:27	Discussion
8:30	Maculopathy in Patients with Monoclonal Gammopathy of Undetermined Significance Stephen Smith, MD
8:36	Discussion
8:39	NEI VQF-25 Responsiveness to Changes in Area of Geographic Atrophy in Patients with Age-related Macular Degeneration Neil Bressler, MD
8:45	Discussion
8:48	A Simple OCT-based System for Scoring the Risk of Progression in Eyes with Intermediate Age-related Macular Degeneration SriniVas Sadda, MD
9:54	Discussion
9:57	Prevalence and Natural History of Asymptomatic Macular Neovascularization in Non-exudative Age-related Macular Degeneration Diagnosed with Optical Coherence Tomography Angiography Philip Rosenfeld, MD
9:03	Discussion
9:06	Evaluating Intravitreal Brimonidine Tartrate Drug Delivery System (Brimonidine DDS) in Patients with Geographic Atrophy in a Phase 2 Study William Freeman, MD
9:12	Discussion
9:15	INTRODUCTION OF GUEST OF HONOR — THOMAS AABERG SR, MD Antonio Capone Jr, MD
9:25	REFRESHMENT BREAK/EXHIBITS

IMAGING AND MEDICAL ECONOMICS

PRESIDING OFFICER: Charles Barr, MD

MODERATOR: Andre Witkin, MD

- 9:55 am *New Diagnostic Choroidal and Retinal Signs of Type 1 Neurofibromatosis*
Edoardo Midená, MD
- 10:00 *Ultra-widefield Autofluorescence in ABCA4 Stargardt Disease*
Steven Schwartz, MD
- 10:05 *Features of Posterior Staphylomas Analyzed by Ultra-widefield OCT and 3D MRI*
Kyoko Ohno-Matsui, MD
- 10:10 Choroidal Changes Associated with Serous Macular Detachment in Eyes with Staphyloma or Dome-shaped Macula
Anna Tan, MD
- 10:16 Discussion
- 10:19 OCT-Angiographic Vascular Perfusion Density Mapping Findings in Optic Disc Pit
Netan Choudhry, MD
- 10:25 Discussion
- 10:28 Dueling Imagers: Adaptive Optics SLO Fluorescein Angiography Challenges OCT Angiography
Richard Rosen, MD
- 10:34 Discussion
- 10:37 Power Law Flow Patterns in the Choriocapillaris as Imaged by Optical Coherence Tomography Angiography
Richard Spaide, MD
- 10:43 Discussion
- 10:46 Sensitivity and Specificity of Choroidal Neovascularization Detection with Optical Coherence Tomography Angiography in Age-related Macular Degeneration
Steven Bailey, MD
- 10:52 Discussion
- 10:55 Comparison of Optical Coherence Tomography Angiography Biomarkers for Distinguishing Diabetic Subjects with Varying Levels of Retinopathy from Non-diabetic Healthy Controls
Abtin Shahlaee, MD
- 11:01 Discussion
- 11:04 Intraoperative Ultra-high Speed Swept Source Optical Coherence Tomography (OCT) for Wide-field Imaging, OCT Angiography, and 4D Imaging
Andre Witkin, MD
- 11:10 Discussion
- 11:13 Physician-industry Interactions and Anti-VEGF Utilization among U.S. Ophthalmologists
Stanford Taylor, MD
- 11:19 Discussion
- 11:22 **INVITED PRESENTATION**
Certification in Retina and Its Related Issues
David Parke II, MD
Executive Vice-President and CEO, American Academy of Ophthalmology
- 11:32 Discussion

FRIDAY, SEPTEMBER 16, 2016

11:37 am	RAYMOND R. MARGHERIO AWARD PRESENTATION INTRODUCTION: David Zacks, MD, PhD Spectral-domain Optical Coherence Tomography Imaging of the Retinal Vascular- avascular Junction in Infants with Retinopathy of Prematurity Xi Chen, MD
11:52	J. DONALD M. GASS AWARD INTRODUCTION: George Williams, MD Surveying the Past and Charting a Path Forward for the Successful Treatment of Macular Degeneration with Gene Therapy Techniques Mark Blumenkranz, MD
12:22 pm	ANNUAL BUSINESS MEETING — THE RETINA SOCIETY
12:50 – 1:45	LUNCH
	RETINAL DYSTROPHIES AND DEGENERATIONS PRESIDING OFFICER: Jenny Lim, MD MODERATOR: Thiran Jayasundera, MD
1:45 pm	<i>The Impact of Exercise on the Quality of Life and Progression of Disease in Retinitis Pigmentosa</i> Jiong Yan, MD
1:50	Glucose Re-establishes Cone Outer Segment Synthesis and Function in Retinitis Pigmentosa Henry Kaplan, MD
1:56	Discussion
1:59	The Role of Autophagy in Photoreceptor Degeneration in the P23H Mouse Model of ADRP David Zacks, MD
2:05	Discussion
2:08	Distinguishing Retinitis Pigmentosa from Severe Hydroxychloroquine Toxicity Michael Marmor, MD
2:14	Discussion
2:17	Long-term Outcomes of Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cell Transplantation for Retina Degeneration Ninel Gregori, MD
2:23	Discussion
2:26	Comparing iPSC Derived RPE Cell Cultures and Commonly Used RPE Cell Lines: What a Clinician Should Know Jose Pulido, MD
2:32	Discussion
2:35	Phenotypic Matching for Genetic Confirmation of Retinal Dystrophies Thiran Jayasundera, MD
2:41	Discussion
2:44	Orally Delivered, Synthetic Chromophore Therapy for Inherited Retinal Disease Due to Genetic Defects in the Visual Cycle David Saperstein, MD
2:50	Discussion

2:53 pm	Pathogenesis in Autoimmune Retinopathy John Heckenlively, MD
2:59	Discussion
3:02	North Carolina Macular Dystrophy (NCDR1): Mutations Found Affecting PRDM13 Kent Small, MD
3:08	Discussion
3:11	REFRESHMENT BREAK/EXHIBITS
	INFLAMMATION AND LATE BREAKERS
	PRESIDING OFFICER: Bernard Doft, MD
	MODERATOR: James Folk, MD
3:41 pm	Endophthalmitis After Open Globe Injuries With and Without Retained Intraocular Foreign Bodies Tanuj Banker, MD
3:47	Discussion
3:50	Post-injection Endophthalmitis Rates and Characteristics following Intravitreal Bevacizumab, Ranibizumab and Aflibercept Nadim Rayess, MD
3:56	Discussion
3:59	Do Vancomycin and Amikacin have Synergistic or Additive Effects against MRSA Organisms at the Intravitreal Drug Concentrations used for Endophthalmitis Bernard Doft, MD
4:05	Discussion
4:08	Twenty-four Months' Follow-up of Intravitreal Bevacizumab Injection versus Intravitreal Triamcinolone Acetonide Injection for the Management of Refractory Non-infectious Uveitic Cystoid Macular Edema Fernando Arevalo, MD
4:14	Discussion
4:17	Sarilumab for Non-infectious Uveitis (SARIL-NIU): Results at Sixteen Weeks from the Phase 2 SATURN Study Quan Dong Nguyen, MD
4:23	Discussion
4:26	Corticosteroid Tapering Success with Every-other-month Injections of Intravitreal Sirolimus in Subjects with Active Non-infectious Uveitis of the Posterior Segment (NIU-PS): SAKURA Study 1 Results Thomas Albini, MD
4:32	Discussion
4:35	OCT Angiography of Placoid Related Disorders David Sarraf, MD
4:41	Discussion
4:44	Late Onset Severe Visual Field Loss in Patients with Retinal Vasculitis James Folk, MD
4:50	Discussion
4:53	Variables Related to the Ophthalmoscopic Findings Identified in Infants with Presumed Zika Virus Congenital Infection Mauricio Maia, MD
4:59	Discussion

5:02 pm	LATE BREAKING PRESENTATION
5:08	Discussion
5:11	LATE BREAKING PRESENTATION
5:17	Discussion
5:20	LATE BREAKING PRESENTATION
5:26	Discussion
5:29	ADJOURN

SATURDAY, SEPTEMBER 17, 2016

PEDIATRICS

PRESIDING OFFICER: **Antonio Capone Jr, MD**

MODERATOR: **Baker Hubbard III, MD**

7:30 am	<i>Spectral-domain Optical Coherence Tomography in Older Patients with History of Retinopathy of Prematurity</i> Aristomenis Thanos, MD
7:35	<i>Abnormal Vessels in the Foveal Center in Premature Eyes: An OCT Angiography Study</i> Irena Tsui, MD
7:40	Familial Exudative Vitreoretinopathy: Outcomes of 332 Eyes with Retinal Detachment Yoshihiro Yonekawa, MD
7:46	Discussion
7:49	Immediate Sequential Bilateral Pediatric Vitreoretinal Surgery: An International Multicenter Study Antonio Capone Jr, MD
7:55	Discussion
7:58	Near-term Safety of Intravitreal Bevacizumab and Diode Laser Photocoagulation Treatments for Type 1 Retinopathy of Prematurity Darius Moshfeghi, MD
8:04	Discussion
8:07	National Trends in Retinopathy of Prematurity over Sixteen Years in the United States Ron Adelman, MD
8:13	Discussion
8:16	577-nm Yellow Laser Photocoagulation for Coats Disease Baker Hubbard III, MD
8:22	Discussion

SURGERY II

PRESIDING OFFICER: **Dean Elliott, MD**

MODERATOR: **Cynthia Toth, MD**

8:25 am	<i>Novel Approach to Surgical Trochar Insertion: Advantages of the Autoinserter</i> Brandon Busbee, MD
8:30	<i>27-Gauge Vitrectomy for Vitreoretinal Disorders</i> Christiane Falkner-Radler, MD
8:35	<i>Modulation of Vitrectomy Console Parameters to Minimize Retinal Motion in Small-gauge Vitrectomy for Retinal Detachment</i> Yannek Leiderman, MD

- 8:40 am *Vitreous and Contrast Sensitivity*
Jerry Sebag, MD
- 8:45 *Multiple Intravitreal Methotrexate Injections for the Prevention of Proliferative Vitreoretinopathy
Dean Elliott, MD
- 8:51 *OM-101 Attenuates the Formation of Fibrotic Response Associated with Proliferative Vitreoretinopathy
Ayala Pollack, MD
- 8:57 *Combined Discussion
- 9:00 Four-dimensional OCT-guided Vitreoretinal Surgery with Surgeon-controlled Heads Up Display
Cynthia Toth, MD
- 9:06 Discussion
- 9:09 Fluid-air Exchange during Silicone Oil Removal is Not Effective, but Harmful for Reducing the Residual Silicone Oil
Taiji Sakamoto, MD
- 9:15 Discussion
- 9:18 A Porcine Model for Venous Air Embolism from Fluid Air Exchange
Andrew McClellan, MD
- 9:24 Discussion
- 9:27 Analysis for Pars Plana Vitrectomy Incisions Using Live Bacteria
Omesh Gupta, MD
- 9:33 Discussion
- 9:36 A Single-center, Randomized, Prospective Study Evaluating the Safety and Efficacy of YAG Vitreolysis versus Sham for Symptomatic Weiss Ring Due to Posterior Vitreous Detachment
Chirag Shah, MD
- 9:42 Discussion
- 9:45 REFRESHMENT BREAK/EXHIBITS

AGE-RELATED MACULAR DEGENERATION II

PRESIDING OFFICER: **Daniel Martin, MD**

MODERATOR: **Mary Elizabeth Hartnett, MD**

- 10:15 am *Simultaneous Dexamethasone Intravitreal Implant and Anti-VEGF Therapy for Neovascular Age-related Macular Degeneration Resistant to Anti-VEGF Monotherapy*
Bozho Todorich, MD
- 10:20 *Phase III Studies Comparing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Subjects with Neovascular Age-related Macular Degeneration: Testing an Alternative Treatment Regimen*
Baruch Kuppermann, MD
- 10:25 *Phase I Study of Combination Therapy with Nesvacumab, an Anti-angiopoietin 2 Antibody, and Aflibercept, an Anti-Vascular Endothelial Growth Factor Agent, for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema*
David Boyer, MD
- 10:30 *CNV Lesion Characteristics as a Predictor of Visual Outcome in Wet Age-related Macular Degeneration Patients Receiving Combination Therapy of Intravitreal Ranibizumab and Squalamine Lactate Ophthalmic Solution*
Nauman Chaudhry, MD

10:35 am	Is there a Role for Fluorescein Angiography in the Monitoring of Eyes with Neovascular Age-related Macular Degeneration Receiving Anti-VEGF Therapy? Rahul Khurana, MD
10:41	Discussion
10:44	Are Dilated Fundus Exams Needed for the Management of Neovascular Age-related Macular Degeneration (nAMD)? Daniel Miller, MD
10:50	Discussion
10:53	Response of Eyes with Pigment Epithelial Detachments Treated with Ranibizumab, Including those that developed Retinal Pigment Epithelial Tears: Data from the HARBOR Study Nadia Waheed, MD
10:59	Discussion
11:02	Prospective, Multicenter Study of Aflibercept Treat-and-Extend for Neovascular Age-related Macular Degeneration (ATLAS): One and Two Year Results Murtaza Adam, MD
11:08	Discussion
11:11	A Meta-analysis of Anti-VEGF Treatment Regimens for Neovascular AMD: One Year Results are Driven in Part by the Injection Frequency Thomas Ciulla, MD
11:17	Discussion
11:20	Five-year Outcomes with Anti-VEGF Treatment of Neovascular Age-related Macular Degeneration in the Comparison of Age-related Macular Degeneration Treatment Trials (CATT) Daniel Martin, MD
11:26	Discussion
11:29	Macular Morphology and Visual Acuity at Year 5 of the Comparison of Age-related Macular Degeneration Treatment Trials (CATT) Glenn Jaffe, MD
11:35	Discussion
11:38	Thy-1 Induces Activation and Migration of Choroidal Endothelial Cells: Relevance to Neovascular Age-related Macular Degeneration Mary Elizabeth Hartnett, MD
11:44	Discussion
11:47	Semaphorins Inhibit Choroidal Neovascularization Shlomit Schaal, MD
11:53	Discussion
11:56	ADJOURN

POSTERS

PEDIATRICS

POSTER 1 Macular Hole in the Pediatric Population: A Retrospective Review
Audina Berrocal, MD

AGE-RELATED MACULAR DEGENERATION

POSTER 2 High-dose Ranibizumab for Exudation and Hemorrhage in Polypoidal Choroidal Vasculopathy: PEARL 2 Trial
James Lai, MD

POSTER 3 Submacular Hemorrhage in Patients on Novel Oral Anticoagulants (NOACs)
Jonathan Hu, MD

POSTER 4 Management of Choroidal Neovascularization (CNV) through the Implantable Miniature Telescope (IMT)
Melanie Fortin, MD

POSTER 5 Reticular Pseudodrusen and Systemic Disease
Jaclyn Kovach, MD

POSTER 6 Systemic Beta-blockers in Neovascular Age-related Macular Degeneration
Anastasia Traband, MD

POSTER 7 Non-steroidal Anti-inflammatory Drug Use is Not Associated with Age-related Macular Degeneration
Bobbeck Modjtahedi, MD

POSTER 8 Investigation of Risk Alleles for Macular Degeneration among Severe Drusen Phenotypes and Retinal Pigment Epithelial Alterations
Matthew Guess, MD

POSTER 9 RETeval and AMD Patients with Good Visual Acuity
Gloria Wu, MD

POSTER 10 Wet Age-related Macular Degeneration in Asian Americans and non-Asians: An Analysis of Comparative Outcomes
Samuel Kim, MD

POSTER 11 Intravitreal ICON-1 in Patients with Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD): A Phase 2 Study EMERGE
Brian Berger, MD

OTHER MACULAR DISEASE

POSTER 12 The Prevalence of Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry and National Health and Nutrition Examination Survey
Jeffrey Willis, MD

POSTER 13 Frequency of Alternative Use among Intravitreal Anti-vascular Endothelial Growth Factor Drugs
Ravi Parikh, MD

POSTER 14 A Mouse Model of Chloroquine Retinal Toxicity
Leo Kim, MD

POSTER 15 Long-term Follow-up of Persistent Outer Retinal Defects (Micro Holes) following Macular Hole Surgery
Mehrdad Malihi, MD

POSTER 16 Central Serous Chorioretinopathy Secondary to Cushing's Disease
William Carroll, MD

SURGERY

- POSTER 17 Scleral Fixation of an Akreos AO60 Intraocular Lens using Gore-Tex Suture: One Year Outcomes and Comparison to Anterior Chamber Intraocular Lens Placement
Mohammad Khan, MD
- POSTER 18 How does ILM Peeling with Chromovitrectomy Augment Closure of Macular Holes and Resolution of Retinal Schisis?
Ahmet Hondur, MD
- POSTER 19 Open Angle Glaucoma following Surgery for Primary Rhegmatogenous Retinal Detachment
Jonathan Greenberg, MD
- POSTER 20 Silicone Oil Tamponade as a Pharmacological Modulator
Jesse McCann, MD
- POSTER 21 23 and 25 Gauge Pars Plana Vitrectomy have Similar Rates of Clinically Significant Complications
Brock Alonzo, MD
- POSTER 22 In-office Vitrectomy for the Removal of Retained Lens Cortex
Saad Shaikh, MD
- POSTER 23 Is it Worth Operating Lamellar Macular Holes?
Gibran Khurshid, MD
- POSTER 24 Vitreoretinal Disorders in Patients with High Myopia and Pars Plana Vitrectomy
Prarthana Dalal, MD
- POSTER 25 Investigating the Posterior Pole: A Tool and Technique for Post Mortem Tissue Recovery in Eucleated Human Eyes
Jerome Giovinnazzo, MD
- POSTER 26 Surgical Management and Outcomes of Pars Plana Vitrectomy for Late Sequelae of Infectious Endophthalmitis
Jeremy Wolfe, MD
- POSTER 27 OCT Findings in Eyes with Unexpected Visual Loss after Vitrectomy
Sara Haug, MD
- POSTER 28 The Comparison of Regional versus General Anesthesia for Surgical Repair of Open Globe Injuries: A 20-Year Experience
Kimberly Tran, MD
- POSTER 29 Diffuse Epiretinal Pigmentary Deposits after Retinectomy with Silicone Oil
Mira Sachdeva, MD
- POSTER 30 Visual and Anatomical Outcomes of Diabetic Tractional Retinal Detachment Repair
Philip Storey, MD
- POSTER 31 Visual and Anatomic Outcomes of Pars Plana Vitrectomy with Membrane Peel in the Elderly
Matthew Adams, MD
- IMAGING**
- POSTER 32 Diurnal Variations in Luminal and Stromal Areas of Choroid in Normal Eyes
Yoshinori Mitamura, MD
- POSTER 33 OCT Angiography Findings in Acute Macular Neuroretinopathy
Sandeep Randhawa, MD

RETINAL VASCULAR DISEASE

- POSTER 34 Dexamethasone Implant with Rescue Ranibizumab for Treating Macular Edema Secondary to Retinal Vein Occlusion: DRIVEN Study
Sundeep Kasi, MD

INFLAMMATION

- POSTER 35 Sequential Optical Coherence Tomography Changes of Macular Star in Cat Scratch Disease
Ryoji Yanai, MD
- POSTER 36 Analysis of Predisposing Factors and Management Course of Endogenous Fungal Endophthalmitis: A Five-year Experience in a Tertiary Referral Center
Andrew Eller, MD
- POSTER 37 A Literature Review and Update on the Incidence and Microbiology Spectrum of Post-cataract Surgery Endophthalmitis Over Past Two Decades in India
Taraprasad Das, MD
- POSTER 38 Surgical Outcomes of Epiretinal Membranes in Patients with Uveitis
Lisa Faia, MD

DIABETIC RETINOPATHY

- POSTER 39 Accumulation of Acrolein-lys Adduct in the Vitreous Fluid of Proliferative Diabetic Retinopathy
Kousuke Noda, MD
- POSTER 40 Systemic Risks Associated with Treatments for Diabetic Macular Edema: A Cohort Study of 27,664 Patients
Andrew Barkmeier, MD



The Retina Society

ANNUAL MEETING PARTICIPANT REGISTRATION PACKET